On Tuesday the Competition Commission confirmed its launched an investigation into pharmaceutical companies, including Aspen, Pfizer and Roche for their suspected excessive pricing of life saving cancer medication.
Roche is being investigated for it's alleged over pricing of breast cancer medication and Pfizer for lung cancer medication.
Aspen is also being probed for suspected abuse of dominance by charging excessive prices in the provision of cancer medication.
The Cancer Alliance which has lobbied around the exorbitant pricing of medicines.
Xolani Gwala spoke to the alliance's Salome Meye.
Not even the department of health can afford paying R 125 000 as oppose to R 500 000 for public patients.— Salome Meye, Member of the Cancer Alliance (Part of the Fix the Patent Laws Coalition)
We know the cost of manufacturing the drugs is half of what they are offering the department of health for the same drug, one really needs to ask who is making the money and who is benefiting, certainly not the patients in the public or private sector.— Salome Meye, Member of the Cancer Alliance (Part of the Fix the Patent Laws Coalition)
We also have knowledge of other drugs and other companies that we will take to the competition commission to investigate.— Salome Meye, Member of the Cancer Alliance (Part of the Fix the Patent Laws Coalition)
Click on the link below to listen to the full audio...